INOVIO PHARMA (INO)
$1.52
0.02 (1.32%)
INO Stock Quote Delayed 30 Minutes
4 Pharmaceutical Stocks That Aren’t Worth Their Outsized 2020 Gains
Now that companies such as Pfizer, Moderna and AstraZeneca have emerged with viable vaccines against Covid-19, the hype around many pharmaceutical stocks is fading. Here are four stocks investors should be weary of in the weeks ahead.
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
$1.63
Market Cap
59.77M
PE Ratio
-0.38
EPS
-3.9519
Volume (Avg. Vol.)
1.18M
Day's Range
$1.50 - $1.64
52-Week Range
$1.50 - $13.44
Dividend & Yield
N/A (N/A)
INO Stock Predictions, Articles, and INOVIO PHARMA News
Inovio Gets the Go-Ahead But It’s Probably Too Late
Inovio got the go-ahead from the FDA on Nov. 16 to resume its Phase 2 clinical trial. Is INO stock worth betting on this late in the game?
Inovio Pharmaceutical’s FDA Plight Makes It a Highly Risky Bet
INO stock has tumbled in the past few months. Inovio needs the FDA to bail it out by allowing the advanced trials of its vaccine to begin.
The Clock Is Ticking for Inovio Stock
The FDA recently lifted the clinical hold on Inovio's Covid-19 vaccine candidate. The result could mean huge returns for INO stock.
Inovio Has Little to Show for Its Covid-19 Efforts
Inovio Pharmaceuticals has little to show for its Covid-19 efforts. INO stock is not worth more than $2, according to one short-seller.
At This Point, Go Ahead and Count Inovio Pharmaceuticals Out of the Vaccine Race
INO stock is a purely speculative bet. I don't see the company being among the few that deliver a vaccine against Covid-19.
Can Inovio Benefit From All Of Its Vaccine Delays?
Shares of Inovio (NASDAQ:INO) are trading near a six-month low. The company is being battered by delays in getting its Covid-19 vaccine candidate into Phase…
Avoid Taking a Bet on the Deep Correction In Inovio Stock
Small-cap biotechs are inherently challenging. With a failed INO-4800 timeline, INO stock increasingly finds itself back in this group.
Avoid Inovio Pharmaceuticals Stock Until the FDA Greenlights Trials
While I’d like to tell you Inovio Pharmaceuticals is a blood-in-the-streets opportunity, I can’t. Avoid INO stock for now.
Inovio Investors Need FDA to Write Positive Prescription for Stock Gains
The bad news is that the FDA recently halted the Inovio trial. Think about that for a moment. The world is in dire of need of a Covid-19 vaccine and the U.S. is engaged “Operation Warp Speed” to get a vaccine to market, but here's a regulator telling Inovio to pump the brakes.
The FDA’s Questions Aren’t a Deal Breaker for Inovio Stock
INO stock is down but not out as the development of a Covid-19 vaccine is bound to have some bumps in the road.
Could the FDA Be Ready to Crash Inovio’s Hopes and Dreams?
It’s been a month since the FDA put Inovio’s Covid-19 vaccine on partial clinical hold. No news is definitely not good news for INO stock.
Time Is Running Out on Inovio as Other Vaccine Candidates Advance
The FDA's latest decision has dealt a killer blow to INO stock, which was already struggling to keep up with Big Pharma in the vaccine race.
Investors Should Buy the Phase II/III Dip in Inovio
INO stock is in a rough spot of late, but it is poised to bounce back from these temporary setbacks with a strong product portfolio.
Why the FDA’s Inquiry of Inovio Is More Critical Than You Think
INO stock tumbled due to the FDA asking questions about the underlying DNA vaccine. Here’s why you should be concerned.
Avoid Inovio Like the Plague After Its 64% Price Drop
INO stock has fallen more than 60% since June and further declines look imminent as the company struggles with its Covid-19 vaccine.
Inovio Stock Is a Great Long Setup for an Overreaction Trade
A freak-out ensued after the FDA placed a halt on Inovio's Covid-19 vaccine trials, but the price dip is a chance to buy INO stock cheaper.
Avoid Inovio Pharmaceuticals Like the Plague
The pharma is pursuing a Covid-19 vaccine. But INO stock is risky as the company has failed to bring a product to market for 40 years.
Inovio Pharmaceuticals Does Not Need Any More Misfortune
INO stock is plummeting after the FDA put a hold on its INO-4800 vaccine candidate. But by the time Inovio resumes the trial, will a vaccine be needed?
Don’t Count Out Inovio Pharmaceuticals Stock Just Yet
INO stock is now a blood-in-the-street opportunity as Inovio is currently facing a temporary hurdle from the FDA.
Trump Coronavirus News: Why the Market Is Sliding Today
The market is sliding on today on Trump coronavirus news following confirmation that President Donald Trump tested positive.
